Statin drugs deny prostate cancer cells access to needed hormones, delaying disease progression
the ONA take:
Cholesterol-lowering statin drugs were shown to delay disease progression in men with prostate cancer when statins were also initiated with androgen deprivation therapy (ADT), according to a clinical trial from Dana-Farber Cancer Institute.
In the study, men who had been taking statins since the start of ADT went a median of 27.5 months before experiencing disease progression, compared with 17.4 months for men who were not taking statins.
Laboratory studies focusing on the SLCO2B1 protein found that the protein helps a variety of drugs and hormones enter cells, including both statin drugs and dehydroepiandrosterone sulfate (DHEAS), a precursor of testosterone, the hormone that spurs prostate cancer cell growth.
Using laboratory-grown prostate cancer cell lines, the researchers found that statin drugs monopolized available SLCO2B1 thereby depriving prostate cancer cells of the hormones they need to grow.
The trial involved 926 patients, and 70% of participants experienced disease progression during a 6-year period.
Although this mechanism by which statins may work in prostate cancer can improve patient outcomes, the researchers state that further study is needed to validate their findings.
Statins were shown to delay disease progression in men with prostate cancer when statins were also initiated with ADT.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- MRD Negativity Associated With Prolonged Survival in Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|